Previous immunohistochemistry studies have tested p53 and Rb as potential biomarkers to differentiate leiomyosarcomas from leiomyomas, but single markers were insufficient, leading to recommendations for using a multi-marker immunohistochemistry panel [44, 45]. This evidence concerns the gene TP53 and leiomyosarcoma.